Pharmacist Perceptions Toward Screening, Brief Intervention, and Referral to Treatment for Prescription Opioid Misuse: Initial Instrument Reliability and Validity by Fouts, Tara
PHARMACIST PERCEPTIONS TOWARD SCREENING, BRIEF INTERVENTION, 
AND REFERRAL TO TREATMENT FOR PRESCRIPTION OPIOID MISUSE: 
INITIAL INSTRUMENT RELIABILITY AND VALIDITY 
by 
Tara Fouts 
 
 
 
 
 
 
 
 
 
A thesis  
submitted in partial fulfillment 
of the requirements for the degree of 
Master of Health Science in Health Promotion 
Boise State University 
 
December 2019  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2019 
Tara Fouts 
ALL RIGHTS RESERVED  
BOISE STATE UNIVERSITY GRADUATE COLLEGE 
 
 
DEFENSE COMMITTEE AND FINAL READING APPROVALS 
 
 
of the thesis submitted by 
 
 
Tara Fouts 
 
 
Thesis Title: Pharmacist Perceptions Toward Screening, Brief Intervention, and 
Referral to Treatment: Initial Instrument Reliability and Validity 
 
Date of Final Oral Examination: 23 October 2019 
 
The following individuals read and discussed the thesis submitted by student Tara Fouts, 
and they evaluated the student’s presentation and response to questions during the final 
oral examination. They found that the student passed the final oral examination. 
 
Megan Smith, Ph.D.    Co-Chair, Supervisory Committee 
 
Sarah Toevs, Ph.D.    Co-Chair, Supervisory Committee 
 
Mike Mann, Ph.D.    Member, Supervisory Committee 
 
The final reading approval of the thesis was granted by Sarah Toevs, Ph.D., Chair of the 
Supervisory Committee. The thesis was approved by the Graduate College. 
 
iv 
ACKNOWLEDGEMENTS 
Thank you to all those who contributed to making this study possible. I would like 
to thank my supervisory Committee: Dr. Megan Smith, Dr. Sarah Toevs, and Dr. Mike 
Mann, for their ongoing support, inspiration, and encouragement. I would like to extend a 
special thank you to Dr. Megan Smith for your reassuring voice and guidance through 
this project, especially the statistical analysis and write-up. Thank you to the expert panel 
members who took the time to review the questionnaire, provide feedback, and talk 
through ideas with me in-person or on the phone. A special thank you to Dr. Cathy 
Oliphant for your support in the early stages of the study. I would also like to thank the 
Idaho Board of Pharmacy for quickly responding to questions and their willingness to 
help a graduate student.  
I would like to thank my friends and family. Scott, thank you for your ongoing 
words of encouragement, support, and love. I appreciate you always being an empathetic 
ear during the ups and downs in the Master’s program. Lastly, thank you to the Health 
Policy and Promotion team at Central District Health for being the best support system. 
You are the most caring, passionate, idea-generating, and inspirational group of people I 
have had the opportunity to work with.
v 
ABSTRACT 
Prescription opioid misuse has become a growing problem in the United States, 
and there has been a significant increase in the number of nonfatal overdose and overdose 
deaths since the 1990s. Idaho has also experienced an increase in the number of drug-
induced deaths over time, increasing nearly 30% from 2012 to 2016. The Centers for 
Disease Control and Prevention indicates overprescribing and dispensing of prescription 
opioids is a main driver to the increase in overdoses. Evidence-based early intervention 
methods, such as screening, brief intervention, and referral to treatment (SBIRT), can be 
utilized in healthcare settings to identify risky behaviors among individuals who may not 
be seeking help for substance problems. However, limited research has been done to 
examine SBIRT in a pharmacy setting and in pharmacist perceptions toward performing 
SBIRT for prescription opioid misuse.  
The purpose of this study was to develop an instrument based on the Theory of 
Planned Behavior (TPB) to measure pharmacist perceptions toward using SBIRT for 
prescription misuse and then test initial validity and reliability. To construct appropriate 
questions, survey items for attitude, subjective norms, perceived behavioral control, past 
behavior, and intention were developed from a previous TPB instrument on the 
utilization of the prescription monitoring program. After data was collected, 
psychometric testing was initiated and included factor analysis, testing the internal 
consistency of the subscales, and a correlation to determine the degree of similarity 
between subscales. A Principal Component Analysis (PCA) was used to extract factors in 
vi 
this study with a non-orthogonal rotation (Direct Oblimin). Items were retained if they 
loaded onto a factor at |0.4| or higher. Findings supported the eight-factor solution that 
was conceptually hypothesized with strong internal consistency for each construct. 
Cronbach’s alpha scores were 0.7 and above for all factors except for past behavior. 
These results offer a foundation for future research to build on the instrument and inform 
interventions that may shape pharmacist readiness in prescription misuse early 
intervention strategies. 
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CHAPTER ONE: INTRODUCTION 
Prescription opioid misuse has become a growing problem in the United States, 
and there has been a significant increase in the number of overdose and overdose deaths 
since the 1990s. According to the Centers for Disease Control and Prevention (CDC), 
two out of three drug overdose deaths involved prescription or illicit opioids (Hedegaard, 
Miniño, & Warner, 2018). Idaho has also experienced an increase in the number of drug-
induced deaths over time, increasing nearly 30% from 2012 to 2016 (Drug-Induced 
Deaths: Idaho Residents 2016 summary, 2017). The CDC indicates overprescribing and 
dispensing of prescription opioids is a main driver to the increase in overdoses.   
Statement of the Problem 
According to the National Survey on Drug Use and Health (NSDUH), Idaho’s 
estimated 2015-2016 prevalence of pain reliever misuse in the past year was 5.09% for 
ages 12 years and up, and the rate was even higher for those 18-25 years of age (9.77%), 
both exceed the estimated national rates. Additionally, NSDUH estimated approximately 
104,000 people ages 12 years old and up to have a substance use disorder (SUD) in 
Idaho, and yet 96,000 Idahoans needed but did not receive treatment in a specialty facility 
for SUD (National Survey for Drug Use and Health, 2015-2016). Although NSDUH 
found the majority of people who misused prescription pain relievers in the past year 
obtained the medication from a friend or relative (53%), 35.4% obtained the pain 
medication through a prescription(s) from a provider.  
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Evidence-based early intervention methods, such as screening, brief intervention, 
and referral to treatment (SBIRT), can be utilized in healthcare settings to identify risky 
behaviors among individuals who may not be seeking help for substance problems 
(Substance Abuse and Mental Health Services Administration  2011). As part of a team-
based approach, pharmacists have the potential to mitigate harm in instances of early 
prescription opioid misuse before risky behavior reaches a diagnosable level.  
Purpose of this Study 
The focus of this research was to develop an instrument that could accurately 
assess community pharmacists’ perceptions towards performing SBIRT in their practice 
setting. This was completed by adapting a Theory of Planned Behavior (TPB) 
questionnaire used to examine pharmacists’ perceptions toward utilizing the Prescription 
Monitoring Program (PMP) for opioid misuse and administering a pilot study to perform 
initial psychometric tests. The TPB constructs in the instrument examine attitude, 
subjective norms, and perceived behavioral control in relation to behavioral intention and 
past behavior.  
Justification of the Study 
Misused medications are often obtained through a pharmacy (Cicero et al., 2011). 
Additionally, pharmacists are considered the most accessible and trusted health 
professional whose doctorate-level training can help address gaps in primary care, 
especially in health professional shortage areas (Manolakis & Skelton, 2010). There is 
promising research on the effectiveness of SBIRT in reducing risky alcohol and 
substance use behaviors and improving short-term health outcomes (United States, 2012). 
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However, limited research has been done to examine SBIRT in a pharmacy setting and in 
pharmacist perceptions toward performing SBIRT for prescription opioid misuse.  
Research Questions 
The purpose of this study was to develop a valid and reliable instrument based on 
the Theory of Planned Behavior to measure pharmacist perceptions toward deploying 
SBIRT for prescription misuse. Therefore, the overall research question was: can the 
instrument that measures the constructs in TPB be reliable and valid? From this overall 
research question, three additional research questions were created: 
1. Does the instrument achieve face and content validity? 
2. Are the attitude, subjective norms, perceived behavioral control, intention, and 
past behavior subscales internally consistent?  
3. Do the underlying factor structures in the subscales support the theoretical 
framework? 
Findings from this study will inform future psychometric testing on the 
instrument and potential points of education that would build readiness to implement 
SBIRT in a pharmacy setting.  
Delimitations 
1. The study was conducted on licensed pharmacists practicing in the state of Idaho 
at the time of the study.  
2. Participants included actively practicing pharmacists that were registered to the 
Idaho Board of Pharmacy’s Prescription Monitoring Program (PMP) database 
with an active email address.   
3. Data were collected from March -April 2019.  
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Limitations 
1. The survey instrument was adapted from a Theory of Planned Behavior 
questionnaire used in two previous studies rather than eliciting measures 
through qualitative methods.  
2. There was no previous study or instrument to compare results to for 
concurrent validity or test-retest reliability.  
3. Data were self-reported and responses may not have been candid.  
4. Participants that responded to the survey may not have been representative of 
all pharmacists practicing in Idaho.  
5. Participants may have different understandings of the Screening, Brief 
Intervention, and Referral to Treatment practice.  
Assumptions 
1. Survey items that were adapted in this study were based on utilization of the 
Prescription Monitoring Program, which can be considered the first step to 
screening for misuse. The intended audience, context, and time of the 
behavior remained the same. 
2. Definitions were provided in the instrument to provide a basic understanding 
of the SBIRT steps.  
3. Data collected in this pilot would be useful for further instrument 
psychometric testing and future SBIRT training and piloting implementation 
in a pharmacy setting.  
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Definition of Terms 
• Community pharmacy: Pharmacy practiced in various retail settings 
such as independent pharmacies, chain stores, food stores, where 
prescription orders are dispensed outside an inpatient hospital setting that 
allows the public access to medications when needed.  
• SBIRT: Screening, Brief Intervention, and Referral to Treatment is a 
comprehensive, evidence-based public health approach used to identify, 
reduce, and prevent problematic use, abuse, and dependence of alcohol 
and drugs. It is useful in disrupting the development of use disorders.  
• Screening: Use of a validated universal tool to quickly assess a patient for 
risky substance use behaviors, and who may already have a substance use 
disorder, and identify appropriate level of intervention.  
• Brief Intervention: A time-limited strategy where a healthcare 
professional engages patients showing risky behaviors in a short 
conversation with a focus on increasing insight in substance use and 
motivating change.  
• Referral to Treatment: In instances where more advanced treatment is 
necessary, a healthcare professional provides a referral to brief therapy or 
a higher level of care when a patient’s screen indicates additional services.   
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CHAPTER TWO: LITERATURE REVIEW 
This chapter provides information on the role of a community pharmacist in the 
opioid crisis. This chapter will also review the literature relevant to this study on 
Screening, Brief Intervention, and Referral to Treatment, SBIRT in a pharmacy setting, 
and the Theory of Planned Behavior.  
Community Pharmacists in the Opioid Crisis 
Community pharmacists remain one of the most accessible health professionals in 
the healthcare system and are often under-utilized in a public health capacity. Among 
many tasks, community pharmacists are frontline professionals responsible for dispensing 
medications, ensuring the legitimacy of prescriptions, monitoring drug utilization, and 
maintaining links with primary care and other health professionals (World Health 
Organization, 1988). The role of pharmacy has evolved from traditional dispensing 
practices to support public health initiatives through providing immunizations (Ndiaye et 
al., 2003) and health screenings such as influenza testing (Klepser et al., 2018). In some 
states, the pharmacist’s role has also expanded to medication therapy management 
(Casserlie & Mager, 2016) and chronic disease state management (Schuessler, Ruisinger, 
Hare, Prohaska, & Melton, 2016). Today, amidst the public health crisis in opioid-related 
overdoses, the American Society for Health-System Pharmacists (ASHP) supports 
pharmacists’ active involvement in reducing the negative effects substance misuse has on 
society, health systems, and the pharmacy profession (2016).  
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As part of a comprehensive approach, several national pharmacy organizations 
have stressed the importance of the pharmacist’s role in responding to the opioid crisis 
due to their expertise and accessibility. Pharmacists are well positioned to exercise 
professional judgment to balance patients’ legitimate medical need for prescription 
opioids with the need to prevent diversion, misuse, dependence, and substance use 
disorders (American Pharmacists Association, 2018; The College of Psychiatric and 
Neurologic Pharmacists, 2016). One study found that 86% of the pharmacists surveyed 
had concerns about prescription opioid use in several patients, and the number of patients 
they were concerned about was positively correlated to the number of patients on opioids 
for chronic pain (Kahan et al., 2011). In addition to educating and counseling patients on 
safe use, storage, and disposal of medications, pharmacists have access to screening tools 
such as the Prescription Monitoring Program (PMP). The PMP allows pharmacists to 
verify the validity of a prescription and assess for “red flags” in prescribing or dispensing 
history. An educational document published by the College of Psychiatric and Neurologic 
Pharmacists, Opioid Use Disorder: Interventions for Community Pharmacists (2016), 
outlines additional strategies for public-facing pharmacists to deploy. These strategies 
include increasing access to naloxone (an opioid overdose reversal medication), 
developing an intervention resource list for patients, and talking with patients about SUD. 
To reduce the risk of diversion and opioid-related overdoses, pharmacies have also 
participated in and promoted medication take-back programs to reduce the amount of 
available controlled substances (Strand, Eukel, & Burck, 2019).  
While the aforementioned efforts have made an impact on the opioid crisis for 
diversion and individuals who may have a SUD, more pharmacy-involved interventions 
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need to focus on preventive patient care. Proactive approaches utilizing pharmacists in 
underserved rural areas are particularly important where individuals have a higher risk for 
opioid misuse than their urban counterparts (Cochran, Engel, Hruschak, & Tarter, 2016). 
Furthermore, ASHP supports pharmacists in the identification of patients who may have 
substance misuse problems and referring those patients to appropriate resources for 
further evaluation and treatment (2016).  
Screening Brief Intervention and Referral to Treatment 
Screening, brief intervention, and referral to treatment (SBIRT) is a public health 
approach to early intervention for risky alcohol, tobacco, and other substance use 
behaviors (SAMHSA, 2011). SBIRT is based on the Institute of Medicine report that 
recognized substance use occurs on a continuum of severity and calls for integrated 
service systems to fill gaps between primary prevention and intensive treatment for SUD 
(1990). SBIRT is designed for use by professionals who do not specialize in addiction 
treatment and is relatively easy to learn by diverse health professionals. In 2003, SBIRT 
was funded across the U.S. by the Substance Abuse and Mental Health Services 
Administration (SAMHSA) in various settings such as primary care offices and college 
campuses (SAMHSA, 2011). The SBIRT model uses three basic elements in the process: 
(1) universal screening, (2) if screening indicates moderate risk a brief intervention is 
used to motivate change in behavior, and (3) a referral to treatment or additional services 
if the screening indicates high-risk behavior.  
A brief universal screening, typically taking about 5-10 minutes to complete, 
addresses specific behaviors. Because the screening is done with all patients and takes 
little time, professionals working in busy practices may more generally accept SBIRT 
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(SAMHSA, 2011). If individuals screen positive, then the brief intervention uses 
motivational interviewing to provide feedback and advice to facilitate behavior change. 
The screening process may also assist in connecting patients to preventive services such 
as diversion reduction services, access to naloxone, and coordination of care services 
(Pringle, Cochran, & Aruru, 2019). In instances when individuals screen for substance 
dependence or a use disorder, a referral to a specialty treatment provider should be made. 
In a primary care setting, approximately 5%-20% of screened patients are positive for 
some level of substance misuse and only 3%-4% need to be referred (SAMHSA, 2011). 
The flow for the SBIRT process is shown in Figure 2.1. 
 
 
Figure 2.1 Flow Chart for the SBIRT process 
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Effectiveness of SBIRT 
There is substantial research that supports the efficacy of SBIRT at reducing 
hazardous alcohol use (Beich, Thorsen, & Rollnick, 2003; Bien, Miller, and Tonigan, 
1993; Kaner et al., 2009) and a growing body of research that supports the effectiveness 
at reducing substance use (Barbor, Del Boca, & Bray, 2017). Similar to alcohol use, licit 
and illicit substance use conditions can occur across a continuum of severity but are 
typically only identified and treated when it becomes severe. In respect to prescription 
misuse, Zahradnik et al. (2009) found that brief intervention led to a reduction in 
prescription drug consumption, including opioids.  
SBIRT in Pharmacy 
Pharmacists frequently encounter patients at risk for prescription misuse, 
dependence, diversion, and use disorders. Leong, Alessi-Severini, Sareen, Enns, and 
Bolton (2016) found that the most common reasons a patient would request an early 
prescription opioid refill or duplication of prescription refills are lost medication, going 
out of town, and stolen medications. While the majority of pharmacists denied the 
prescription refill, factors such as familiarity with the patient and easy access to medical 
history facilitated the filling request. Pharmacists are well positioned to utilize SBIRT to 
inform the decision-making process in instances of early refill requests and to identify 
potential opioid misuse in their practice. SBIRT is versatile, brief, and easy to learn. 
However, unlike the extensive research on use in a primary care setting, few studies have 
reviewed the SBIRT model in a pharmacy setting. 
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Screening 
Of the emerging studies on SBIRT-type strategies in a pharmacy setting, many 
investigate screening and/or brief intervention (SBI) or referral to treatment. A survey 
administered to Utah and Texas pharmacists found a high level of interest in helping 
patients with prescription opioid use problems, with 50.2% of respondents agreeing that a 
pharmacy would be a good setting to test if screening and brief intervention could help 
patients misusing prescription opioids. Additionally, over 40% of the surveyed 
pharmacists indicated they already screen for prescription opioid misuse (Cochran, Field, 
Lawson, & Erikson, 2013). Authors note that pharmacists’ interest and their practice 
setting are important factors to consider when implementing pharmacy-based misuse 
interventions. A 2015 study conducted by Cochran, Field, and Lawson found that 
practicing in a chain pharmacy was the strongest predictor of screening, and pharmacists 
who did screen had practiced, on average, three years longer than those who did not 
report screening. Pharmacists who reported feeling awkward inquiring about prescription 
opioid misuse in patients were 58% less likely to screen, and those who had inadequate 
access to screening tools were 44% less likely to report screening. In contrast, 
pharmacists indicated quick and easy screening tools would motivate them to work with 
patients who misused medications (Cochran et al., 2015). Pharmacists who felt electronic 
prescription record systems were useful as a screening tool were also 75% more likely to 
screen at the time of the study (Cochran, Field, & Lawson, 2015).  
A 2019 study assessed the feasibility of community pharmacists screening 
patients using the Opioid Risk Tool, a validated tool used in pain clinics, to identify 
opioid misuse. If patients screened positive, the pharmacists offered services including 
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counseling patients on the potential for SUD. The six-week pilot study showed that, of 
the 107 patients screened, 25% were identified at some risk of misuse, similar to rates in 
other settings. Of the patients screened, 71 received information about medication take-
back programs and 17 were provided information on community support services (Strand 
et al., 2019). Preliminary research on screening for opioid misuse and use disorder in a 
community pharmacy setting found that an objective assessment helped identify patients 
at risk for misuse and facilitate a discussion on use disorders (Strand et al., 2019). 
Additionally, screening for misuse increased the likelihood of discussing potential opioid 
misuse (Cochran et al., 2015). Leong et al. (2016) found that nearly 50% of pharmacists 
felt confident in their ability to identify high-risk patients for prescription misuse; 
however, 44% of respondents felt they were not confident in their ability to intervene if 
they did suspect misuse.  
Brief Intervention 
Regarding providing a brief intervention, chain pharmacists were again the largest 
group that reported currently engaging patients in a discussion on prescription opioid 
misuse while hospital system pharmacists were the least likely group (Cochran et al., 
2015). Authors also found that pharmacists who held a bachelor-level degree were the 
largest group currently discussing misuse with patients (54.8%) while doctorate-level 
pharmacists were the largest group who did not discuss misuse (50.5%).  
In 2018, Riley and Alemagno evaluated patient and pharmacist acceptability of 
five opioid misuse interventions in Ohio. Two of the five interventions included 
counseling patients on the risks associated with opioid misuse (brief intervention) and 
referring patients to treatment programs. Patients and pharmacists alike demonstrated 
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some level of support for counseling on risks associated with opioid misuse. However, 
only 32% of patients indicated that a pharmacist had ever counseled them on proper 
prescription opioid use and potential risks like an addiction (Riley & Alemango, 2018). 
From the pharmacists’ perspective, the depth of the patient-pharmacist relationship may 
affect the decision to engage in a discussion about prescription misuse (Hagemeier et al., 
2016). 
Referral to Treatment 
In respect to referring patients to treatment, Riley and Alemango (2018) found 
that both patients and pharmacists reported more cautious support. Authors also asked 
pharmacists if they have ever referred a patient to local treatment resources, and 
interestingly, 25% of pharmacists reported they had at least once in their professional 
career. However, only 1.6% of patients reported receiving treatment resources from a 
pharmacist. Similarly, Hagemeier, Alamian, Pack and Murawski (2014) found that 
approximately 25% of 637 Tennessee community pharmacists surveyed have previously 
provided addiction treatment facility information to patients and only 13% had addiction 
treatment facility information readily available. Hagemeier et al. (2014) also found an 
association in pharmacists providing addiction treatment facility information to patient(s) 
with being male, increased number of hours worked per week, having information readily 
available in their pharmacy, higher self-efficacy beliefs, and participation in prescription 
opioid abuse-specific continuing education. Unlike both screening and brief intervention, 
pharmacists employed in a chain or grocery store setting were significantly less likely to 
provide treatment information than pharmacists in an independent setting were. 
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Barriers and Facilitators to SBIRT 
Several studies indicated barriers to effectively use SBIRT-type interventions in a 
pharmacy setting. First, the need for additional training and education surfaced as a 
barrier (Cochran et al., 2015; Lafferty, Hunter, & Marsh, 2006). Pharmacists were less 
likely to discuss prescription misuse with patients if they felt they had too little training in 
addiction and helping patients with substance use disorders (Cochran et al., 2014; 
Wenthur et al., 2013). A survey administered to Florida pharmacists found that only 38% 
of respondents indicated having “much” to “very much” knowledge about addiction as a 
disease (Lafferty et al., 2006). Additionally, 46.9% of pharmacists reported rarely or 
never counseling patients on addictive medication even though similar rates (46.7%) 
were reported of having “much” knowledge about counseling and intervening in misuse 
(Lafferty et al., 2006). Based on these findings, authors note pharmacists should stay up-
to-date on appropriate interventions for substance abuse and treatment resources for 
substance use disorder. Wenthur et al. (2013) found that both student pharmacists and 
practitioners were interested in additional addiction education, and many believed it 
would positively affect their ability to counsel patients and better use local treatment 
resources. When it came to practicing pharmacists, 75.7% of respondents felt the 
pharmacy curriculum needed to include drug withdrawal and treatment, available 
addiction resources (57.9%), intervention (40.5%), and recovery options (43.7%) 
(Wenthur et al., 2013). Even though student pharmacists rated it lower in importance than 
practicing pharmacists, student pharmacists also rated addiction-related topics as high 
importance. Interestingly, the more practice experience gained in both students and 
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practitioners, the more important addiction-related topics became to them (Wenthur et al., 
2013).  
Confidence also emerged as a potential barrier to performing behaviors in SBIRT. 
Hagemeier et al. (2014) found that the majority of pharmacists were confident in their 
ability to identify misuse in patients, but few were confident in their interpersonal skills 
regarding prescription misuse. Pharmacists appear more confident in their ability to 
screen for or detect misuse and less confidence in their ability to briefly intervene with a 
discussion about addiction (Hagemeier et al., 2014; Lafferty et al., 2006). Furthermore, 
only 18% of respondents were confident in their ability to detect misuse, discuss misuse 
with patients, counsel on addiction, and discuss treatment options with patients. The 
number of years practiced, practice setting and gender appeared to influence confidence. 
Additionally, pharmacists who felt they had a right to ask about misuse were twice as 
likely to engage patients in a discussion about it (Cochran et al., 2015). Pharmacists who 
felt their patients believed the pharmacists had a right to ask were 88% more likely to 
discuss misuse.  
Pharmacists also identified employer type as a potential barrier to screening and 
briefly intervening, particularly in chain or supermarket practice settings, and fear from 
employer repercussions (Hagemeier et al., 2014). In addition to employer type, fear of 
patient’s response, personal safety, quick easy access to tools and information, and time 
constraints were identified as barriers (Hagemeier et al., 2014; Hagemeier et al., 2016; 
Cochran et al., 2015; Fleming, Bapat, & Varisco, 2019).  
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Theoretical Framework: Theory of Planned Behavior 
The Theory of Planned Behavior (TPB), based on the Theory of Reasoned action, 
is a theoretical model used to predict individual behaviors (Ajzen, 1991). The TPB is 
designed to examine the relationships between intentions, behaviors, perceptions, 
attitudes, and motivations. TPB posits that behavioral intention determines actual 
behavioral performance, and Ajzen (1991) states that intention can be determined by 
three constructs: attitude, subjective norms, and perceived behavioral control. In this 
context, attitude can be defined as the “degree to which a person has a favorable or 
unfavorable evaluation or appraisal…” towards the behavior (Ajzen, 1991). Subjective 
norms are the perceived social pressure from close personal and professional 
relationships to perform or not perform the behavior. Lastly, perceived behavioral control 
is the perceived ease or difficulty of doing that behavior by reflecting on past experiences 
and anticipating future obstacles or difficulties (Ajzen, 1991). TPB is an appropriate 
theory to explore beliefs that may facilitate or deter pharmacists’ adopting SBIRT as an 
early intervention.   
Ajzen and Fishbein (1980) recognize external factors that can also influence 
behavioral intention and performance but are not considered a construct in the model. 
External factors include demographics like age, gender, and education level. The TPB 
also assumes that individuals will have the resources and opportunity to perform the 
behavior in question. According to Ajzen (1991), TPB can be modifiable and additional 
variables can be included in the model. Consequentially, this study will also include 
perceived contextual barriers in addition to attitude, subjective norms, and perceived 
behavioral control. See Figure 2.2 for the TPB conceptual model used in this study.  
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Figure 2.2 Theory of Planned Behavior Model 
Theory of Planned Behavior in a Pharmacy Setting 
Previous studies have used the TPB to gain a better understanding of health 
professionals’ behaviors and to investigate perceptions across a broad range of behaviors 
(Armitage & Conner, 2001). TPB has been utilized as a theoretical framework in several 
prescription drug misuse studies in pharmacy including intention to utilize the PMP 
database (Fleming et al., 2014; Gavaza, Fleming, & Barner, 2014), intention to provide 
medication disposal education (Tai, Hata, Wu, Frausto, & Law, 2016), and intention to 
report adverse drug events to the FDA (Gavaza & Bui, 2012). The TPB has also been 
used to explore pharmacist perceptions and behavioral intention toward the three 
behaviors in SBIRT. For example, a Tennessee study used the TPB to explored 
pharmacists’ perceptions toward initiating communication with patients about 
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prescription drug misuse and if they see it as their role to potentially intervene in 
circumstances such as use disorders (Hagemeier et al., 2014). However, no single study 
has explored all three SBIRT behaviors in a pharmacy setting using the TPB.  
Conclusion 
Pharmacists are encouraged to address and respond to the increase in prescription 
drug misuse, and the research indicates that some pharmacists already occasionally 
screen, briefly intervene, or refer patients to treatment for substance misuse. Studies that 
have explored pharmacists’ perceptions towards intervening indicates that quick and easy 
access to tools and information influence their decision to screen, briefly intervene, and 
refer to treatment. Previous studies also suggest that pharmacists may experience practice 
setting-related or personal barriers to using SBIRT. These barriers listed in the research 
include gender, education, experience, time constraints, and fear from employer or 
patients’ reactions. Despite emerging research evaluating the possibility of SBIRT in a 
pharmacy setting, it is still largely unknown what pharmacists’ perceptions toward 
implementing all steps in the evidence-based practice are for prescription misuse.
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CHAPTER THREE: METHODOLOGY 
Introduction 
This chapter describes the research methodology used in the design, construction, 
and evaluation of the survey tool. The first section details the first steps in conceptual 
design and instrument development. The second section details the data collection phase 
including the process to disseminate the test survey and sample participants. The final 
section describes the process for data analysis, specifically testing the reliability and 
validity of the survey tool.  The proposal of this study was approved by Boise State 
University’s Institutional Review Board (Appendix A).  
Instrument Design 
The survey instrument development was done in three steps. These steps include 
(1) defining behavior and research population (2) adapting items from a previously 
reviewed TPB survey instrument, and (3) submitting the proposed items to a panel of 
expert reviewers to ensure content validity.  
Defining Behaviors 
Fishbein and Ajzen (2010) instruct the first step as clearly defining the behavior 
of interest in terms of target, action, context, and time (TACT). Specifically applied to 
pharmacists currently practicing in Idaho and accessible to the public, the TACT goes as 
follows: pharmacists (target) Screening Brief Intervention and Referral to Treatment 
(action) to identify and provide early intervention for nondependent risky behaviors in the 
pharmacy (context) when patients pick up their prescription (time). For this study, SBIRT 
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was divided into three behaviors (1) screening for risky behaviors, (2) briefly intervening 
with feedback and advice, and (3) referring to treatment if needed.  
Identifying Survey Items and Scale 
Secondly, to construct appropriate questions, survey items for attitude, subjective 
norms, perceived behavioral control, past behavior, and intention were developed based 
on the TPB instrument from Gavaza et al. (2014). Gavaza, Fleming, and Barner’s (2014) 
TPB instrument items were developed from focus groups and elicitation interviews with 
pharmacists in Texas on intention to utilize the Prescription Monitoring Program (PMP) 
to help identify diversion or other controlled substance misuses (Fleming et al., 2014). 
Items were adapted to reflect each behavior in SBIRT to capture if pharmacists’ 
perceptions varied across each step in the process. A matrix of TPB constructs and 
SBIRT questions can be found in Appendix C. 
Additionally, 11 demographic items and one question to capture perceived 
barriers were added to the instrument. Barriers to counseling patients with mental health 
disorders by Panesar (2016) were used to inform perceived barriers in this study. 
Demographic items included gender, age, education level, practice setting, number of 
years practicing pharmacy, number of hours working in a community setting, and 
estimated opioid prescriptions filled in a week. Attitude was made up of 9 items, 30 items 
for subjective norms, 11 items for perceived behavioral control, and 12 items for past 
behavior and intention. All items for the TPB construct used a 7-point bi-polar scale 
ranging from extremely unlikely (-3) to extremely likely (+3) with 0 being neutral 
(Glanz, Lewis, & Rimer, 1997). The survey instrument included 74 items to capture 
perceptions for the three SBIRT behaviors and demographics. 
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Content Validation  
Expert opinions were solicited to aid in assessing the content validity and clarity 
of the survey instrument. Five individuals made up the expert panel – four individuals 
with pharmacy background and expertise and one professional with expertise in 
substance abuse prevention and health behavior theory. These experts were chosen 
because each has an interest and worked with substance misuse issues in different 
capacities. Each reviewer was sent an email with information on the purpose of the study 
and the survey items, including demographics, to provide comments and feedback on. 
Revisions were made to the survey items based upon the feedback and comments from 
the reviewers. Subjective norms questions were narrowed from 30 items to 18 items, 
combining “friends” and “family” into a single item instead of two separate categories. 
Feedback from reviewers also indicated that two items in perceived behavioral control 
were duplicative and therefore were removed. Lastly, perceived contextual barriers were 
reduced to 18 possible barriers with the option for participants to write in a barrier. 
Survey Pilot 
The survey instrument was also pretested with a cohort of Master of Health 
Science (MHS) students. Students enrolled in Program Evaluation were sent a test link to 
access the Qualtrics survey. Students were asked to complete the survey and provide 
feedback on language, survey design, and use of the TPB. Based on feedback from the 
MHS students and the expert panel, revisions were also made to the wording in perceived 
behavioral control and attitude, and definitions of each SBIRT behavior were added for 
participants.  
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Finalized Survey 
In total, 60 items made up the finalized survey instrument. There were 11 
demographic items, 9 items to capture attitude, 18 items for subjective norms, 9 items for 
perceived behavioral control, 12 items for past behavior and intention, and one item for 
perceived barriers. The survey instrument is provided in Appendix D. 
Data Collection 
Participants 
Study participants included pharmacists currently practicing in the state of Idaho 
and were registered for the Idaho Prescription Monitoring Program (PMP), a statewide 
electronic database that tracks data on dispensed controlled substances. The Idaho Board 
of Pharmacy provided a contact list for pharmacists registered to Idaho’s PMP. For this 
study, pharmacists who practice in a hospital setting were excluded from the list to focus 
on those most easily accessible to the public. However, the BOP does not require 
pharmacists to be employed to hold a valid Pharmacist license in Idaho. Additionally, the 
employment status of the pharmacist does not necessarily restrict or grant access to the 
public. For example, a pharmacist shown to work in a hospital setting may also be 
accessible to the public as a freelance pharmacist or with the permission of the hospital 
while working at the hospital. A demographic question on current practice setting to 
identify pharmacists who are registered for the PMP but not practicing (i.e. retirement) 
was used to exclude those responses in the analysis. With the exclusion criteria, there 
were 1,330 pharmacists on the distribution list.
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Data Collection Procedures 
An introductory message and link to the pilot survey were distributed 
electronically to the list of pharmacists provided by the Idaho BOP. The introduction 
message (Appendix B) included a summary of the study, eligibility to participate, time 
expected to complete the online survey, and consent to participate. The survey was 
created, distributed, and collected using Qualtrics. The period for data collection was 
between March 12 and April 18, 2019. A soft distribution to approximately 10% of the 
sample (n=130) was used the first week to correct any issues and the remaining email 
distributions were sent 7 days later. Three email reminders were emailed to unfinished 
respondents. To maintain privacy and confidentiality, all data was collected anonymously 
and no identifying information was obtained. The data was stored in a password-
protected online database until the end of the survey period.   
Data Analysis 
 After data was collected, psychometric testing was initiated. Statistical analyses 
included factor analysis, testing internal consistency reliability of the subscales, and a 
correlation to determine the degree of similarity between subscales.  
Factor Analysis 
A factor analysis was performed to identify factor structure. An Exploratory 
Factor Analysis (EFA) was used to determine if the 48 TPB items followed the 
underlying constructs of the theory and if the items hang together in each of the 
subconstructs. A Principal Component Analysis (PCA) was used to extract factors in this 
study with a non-orthogonal rotation (Direct Oblimin). Overall, eight factors were 
requested based upon the theoretical design of the instrument to index: attitude behavioral 
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intention, attitude evaluation, subjective norms motivation to comply, subjective norms 
normative belief, perceived behavioral control control belief, perceived behavioral 
control perceived power, behavioral intention, and past behavior.  
There were three criteria used to determine factor retention in the analysis. The 
first criteria was the Kaiser-Meyer-Olkin (KMO) measure used to verify sampling 
adequacy and Bartlett’s test of sphericity to test if the variables are correlated enough for 
factor analysis. An acceptable KMO limit was established at 0.5 or above while the 
Bartlett test should be significant, meaning less than 0.05 (Morgan, 2013). Secondly, 
Cattell’s scree plot was used to determine at what point a factor explains little variance. 
In the scree plot, each subsequent factor explains less variance than the factor before it. 
Typically below the “elbow” of the plot factors will explain little variance whereas above 
the “elbow” factors explain considerably more variance. Lastly, interpretability criteria 
including if there were at least three item loadings onto a factor at a significant level, if 
the variables share a conceptual meaning, if the other factor loadings appear to measure a 
different construct, and if there were either high or low loadings onto a factor (Suhr, 
2006). Although significant levels are just guidelines, low factor loadings would typically 
be below |0.30|, but setting the level at |0.50| or above is atypical (Morgan, 2013). 
Therefore, a significant level for an item to load onto a factor was established at |0.40| or 
greater. 
Reliability 
Cronbach’s coefficient alpha, a preferred indicator, was then used to test 
reliability of the survey items (Cohen, 2003). According to Morgan (2013), alpha is 
commonly used to indicate the internal consistency of multi-scale items when the survey 
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has been administered once, such as this case. Cronbach’s alpha is determined by the 
average correlation of each item in the scale with every other item. An acceptable alpha 
score should be 0.70 or higher (Morgan, 2013).   
Correlation 
A Pearson-r correlation was performed on the TPB subscales to examine the 
relationships between the constructs and determine if there was a significant relationship 
between behavioral intention and attitude, subjective norms, and perceived behavioral 
control. A +1 and -1 indicates a strong correlation between variables and 0 indicates no 
effect. (Morgan, 2013). Using Cohen’s guidelines to the interpretation of relationship 
strength, absolute r values less than 0.1 are considered small, absolute r values 0.3>r>0.1 
are considered moderate or medium, and absolute values 0.5>r>0.3 are considered larger 
(Morgan, 2013). 
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CHAPTER FOUR: RESULTS 
A total of 160 online surveys (12% response rate) were captured during the 
collection period with a 68% completion rate. Cases were eliminated from data analysis if 
less than 65% of the survey was complete. Cases were also excluded if participants 
indicated they were retired, not practicing, or if practice setting did not align with the 
study (e.g. specialty home infusion, long-term care facility, pharmaceutical company). As 
a result, 52 cases did not meet the criteria and were eliminated from the analysis. 
Specifically, 42 cases withdrew participation in the early demographics stages of the 
questionnaire and 10 cases were either retired, not working, or excluded due to practice 
setting. In total, 108 cases were used in analysis.  
The descriptive statistics on the demographic data are presented in Table 4.1. 
Female participants represented 53.3% of the sample with 46.7% of male respondents. 
Participants ages ranged from 26 years old to 72 years old (M= 47.8). The majority of 
participants held a doctoral-level degree (80.4%) and there was a wide range in number 
of years practicing pharmacy. In regards to practice setting, 36.1% of participants 
indicated currently working in a drug or grocery store pharmacy, and the second-highest 
category in practice setting was a health system pharmacy at 22.2%. When asked about 
the number of opioid prescriptions they filled each week, 18% indicated zero. However, 
63% of participants filled anywhere between 1-100 opioid prescriptions in a week with 3 
participants indicating they fill over 400. When asked about approximate hours of 
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continuing education related to opioid use disorders, the majority (65.4%) responded 
between 1 and 10 hours of education.
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Table 4.1 Pilot study participant demographic characteristics 
Characteristic Frequency Percentage (%) Total N 
Sex    
Male 50 46.7 107 
Female 57 53.3 107 
Age (mean= 47.8, median=47)    
26-35 25 24 104 
36-45 30 28.8 104 
46-55 23 22.1 104 
56-65 17 16.3 104 
>65 9 8.7 104 
Hours per week working in a 
community pharmacy setting 
   
0 21 20.2 104 
1-10 11 10.6 104 
11-20 9 8.6 104 
21-30 10 9.6 104 
31-40 38 36.6 104 
>40 15 14.4 104 
Years practicing pharmacy    
1-3 14 13.6 103 
4-6 10 9.7 103 
7-10 13 12.6 103 
11-15 16 15.5 103 
16-20 14 13.6 103 
21-25 16 15.5 103 
26-30 6 5.9 103 
>30 14 13.6 103 
Primary Practice Setting    
Grocery or drug store 39 36.1 108 
Independent Pharmacy 19 17.6 108 
Mass Merchandiser 14 13.0 108 
Outpatient/Clinic 12 11.1 108 
Health System Pharmacy 24 22.2 108 
Idaho Public Health District    
PHD 1 13 12.1 107 
PHD 2 8 7.5 107 
PHD 3 12 11.2 107 
PHD 4 37 34.6 107 
PHD 5 13 12.1 107 
PHD 6 13 12.1 107 
PHD 7 11 10.3 107 
Education    
Bachelor 19 17.8 107 
Master 2 1.9 107 
PharmD 86 80.4 107 
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Number of year since completing 
highest degree 
   
1-5 23 21.7 106 
6-10 16 15.1 106 
11-15 15 14.1 106 
16-20 15 14.1 106 
21-30 22 20.8 106 
31-40 9 8.5 106 
>40 6 5.7 106 
Approximate number of Continuing 
Education hours completed for 
Opioid Use disorder 
   
>1 2 2 101 
1-5 41 40.6 101 
6-10 25 24.8 101 
11-15 11 10.9 101 
16-20 11 10.9 101 
21-30 4 3.9 101 
31-40 3 3 101 
>40 4 3.9 101 
Avg. Opioid prescription filled in a 
week 
   
0 18 18 100 
1-50 40 40 100 
51-100 23 23 100 
101-200 9 9 100 
201-300 4 4 100 
300-400 3 3 100 
>400 3 3 100 
 
Factor Analysis 
As previously discussed in the methodology section, this study used the 
Exploratory Factor Analysis (EFA) to examine the factor structures of the survey tool. An 
EFA was conducted on the 48 items based on the five Theory of Planned Behavior 
constructs with non-orthogonal rotation (Direct Oblimin). To determine how many 
factors to extract, a combination of criteria was created: (a) the number of constructs and 
subconstructs in the Theory of Planned Behavior, (b) eigenvalues-greater-than-1 for each 
factor, (c) the scree test, and (d) interpreting item loading factors extracted.  
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Attitude 
 The Kaiser-Meyer-Olkin (KMO) measure verified the sampling adequacy for the 
analysis, KMO = 0.733 (sufficient items for each factor should be 0.70 or greater and 
adequate items at 0.50) (Morgan, 2013). Bartlett’s test of sphericity x2 = 485.058, df = 
36, p = <0.000, indicating that correlations between items were sufficiently large for 
PCA. Two components had eigenvalues over Kaiser’s criterion of 1 and in combination 
explained 64.5% of the variance as shown in Table 4.2. The scree plot, however, showed 
flattening after the third factor, suggesting that a third factor might be interpretable 
(Figure 4.1).  
Table 4.2 Total Variance Explained for Attitude: Factor Solution with PCA 
Extraction 
Factor 
Initial Eigenvalues Rotation Sums of Squared 
Loadings 
 Total % of Variance Cumulative % Total 
1 3.825 42.497 42.497 3.257 
2 1.978 21.975 64.472 2.852 
3 0.874 9.711 74.183    
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The next step was to explore the rotated structure matrix of the two-factor 
solution. Table 4.3 shows the factor loadings after rotation using a structure matrix. The 
items cluster on the same components suggest that items A13 through A16 load onto 
factor one. Items that loaded onto factor one asked participants questions such as 
Q14.1“when the validity of an opioid prescription is in question, I believe it would be 
useful to screen patients for misuse,” and Q15 “I believe it is a pharmacist’s professional 
duty to briefly intervene with feedback and advice when patients show risky prescription 
opioid use.”  Items that loaded onto the second factor included questions such as Q17 
“Overall, prescribers are more responsible than pharmacists for screening patients for 
prescription opioid misuse,” and Q19 “Overall, prescribers are more responsible than 
pharmacists for referring patients to treatment for prescription opioid misuse.” 
Figure 4.1 Nine item screen plot for Attitude 
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  Items A15 and A16 were originally intended to load onto factor two and capture 
values attached to the outcome. However, factor loadings indicate items cluster with 
factor one. Item A16 appears to cross-load on both factors above |0.40|.  
Table 4.3 Attitude factor loadings after rotation 
Item Factor Loadings 
 1 2 
A13 .464 .052 
A14.1 .839 -.217 
A14.2 .846 -.316 
A14.3 .592 .102 
A15 .852 .-339 
A16 .669 -.438 
A17 -.255 .901 
A18 -.087 .885 
A19 -.158 .890 
 
Subjective Norms 
 The KMO measure for the 18 subjective norms items verified the sampling 
adequacy (KMO = 0.778) and Bartlett’s test of sphericity x2 = 1931.633, df = 153, p = 
0.000 indicated factor analysis would be useful. As presented in Table 4.4, five 
components had eigenvalues greater than 1, and the combination explained 82.0% of the 
variance. Factors six and seven were also close to 1, and the scree plot in Figure 4.2 
revealed ambiguous flattening between the fourth and eighth components.  
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Table 4.4 Total Variance Explained for Subjective Norms: Factor Solution with 
PCA Extraction 
Factor 
Initial Eigenvalues Rotation Sums of 
Squared Loadings 
 Total % of Variance Cumulative % Total 
1 6.944 38.578 38.578 4.797 
2 3.352 18.631 57.199 4.269 
3 2.015 11.192 68.391  4.007  
4 1.320 7.333 75.724  4.425  
5 1.128 6.266 81.990  4.396  
6 0.973 5.408 87.398    
7 0.679 3.770 91.168    
 
 
Figure 4.2 Eighteen-item scree plot for Subjective Norms 
However, the TPB Subjective Norms should reflect two underlying latent 
variables: normative belief and motivation to comply. Based on the theoretical model, 
subjective norms were forced to two factors which then explain 57.2% of the variance.  
Table 4.5 shows the factor loadings after rotation using a structure matrix and suggest 
that the items in subjective norms work well with two factors. Items that cluster onto 
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factor one reflect respondents’ motivation to comply with what their supervisor and other 
pharmacists want. Factor one questions include items like Q21.1 “when it comes to 
screening patients for prescription opioid misuse, I want to do what my supervisor thinks 
I should do.” Items S25.1-25.3 asking about motivation to comply concerning friends and 
family correlate strongly to both factors above |0.40|. Items that cluster onto factor two 
ask questions such as Q25.2 “how much do you agree that your friends and family think 
you should briefly intervene with feedback and advice about opioid misuse?” The items 
that cluster onto factor one appear to represent motivation to comply and factor two 
represents normative belief in subjective norms.  
Table 4.5 Subjective Norms factor loadings force to 2 after rotation 
Item Factor Loadings 
 1 2 
S20.1 .054 .712 
S20.2 -.098 .715 
S20.3 .076 .689 
S21.1 .725 .143 
S21.2 .791 .332 
S21.3 .738 .215 
S22.1 .714 .096 
S22.2 .766 .197 
S22.3 .811 .295 
S23.1 .719 .112 
S23.2 .781 .176 
S23.3 .800 .292 
S24.1 .264 .772 
S24.2 .235 .774 
S24.3 .337 .727 
S25.1 .503 .643 
S25.2 .444 .730 
S25.3 .421 .679 
 
Perceived Behavioral Control 
 The KMO measure for the nine items in Perceived behavioral control (PBC) 
indicated acceptable sampling with a KMO = 0.636, and Bartlett’s Test of Sphericity x2 = 
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371.160, df = 36, p = 0.000. Initial analysis showing eigenvalues over 1 indicated three 
interpretable factors for PBC as shown in Table 4.6 and was supported by the scree plot 
in Figure 4.3. The three items that loaded onto factor one included “For me, questioning a 
patient with whom I have a relationship with would be easy,” and “…engaging patients 
in a discussion relating to prescription opioid misuse would be easy for me.” Factor two 
included items regarding the decision to screen, briefly intervene, and refer to treatment 
being beyond the participant’s control. Finally, the third factor appeared to relate to 
confidence in their ability to perform each behavior.  
Table 4.6 Total Variance Explained for PBC: Factor Solution with PCA 
Extraction 
Factor 
Initial Eigenvalues Rotation Sums of Squared 
Loadings 
 Total % of Variance Cumulative % Total 
1 2.959 32.879 32.879 2.383 
2 2.235 24.830 57.710 2.361 
3 1.138 12.640 70.350  2.208  
 
 
Figure 4.3 Nine-item scree plot for PBC 
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The next step was to explore the rotated structure matrix of the factor solution. 
Table 4.7 shows the factor loadings after rotation using a structure matrix. When the 
factor analysis was forced to two factors to align with the TPB PBC constructs, the 
“easy” items P26, 29-30 and “confidence” items P28.1-28.3 loaded onto factor one while 
the control items loaded onto factor two. The two factors explained 57.7% of the variance 
as seen in Table 4.6. The items that cluster on factor one appear to represent perceived 
power, which measures the perceived effect of making behavioral performance difficult 
or easy. Factor two represents control belief in PBC which measures the perceived 
likelihood of occurrence of each facilitating or constraining condition.  
Table 4.7 PBC factor loadings force to 2 after rotation 
Item Factor Loadings 
 1 2 
P26 .731 -.106 
P27.1 -.092 .883 
P27.2 -.095 .922 
P27.3 -.117 .832 
P28.1 .760 -.019 
P28.2 .815 -.005 
P28.3 .567 -.054 
P29 .561 -.136 
P30 .662 -.127 
 
Behavioral Intention 
 Behavioral intention KMO measure verified acceptable sampling for the analysis, 
KMO = .639 and Bartlett’s Test of Sphericity x2 = 314.094, df = 15, p = 0.000 for the six 
items.  Initial factor analysis indicated items load onto two factors shown by the 
eigenvalues over 1 in Table 4.8, and the “elbow” in the scree plot in Figure 4.4 also 
indicates two factors.  
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Table 4.8 Total Variance Explained for Behavioral Intention: Two-Factor 
Solution with PCA Extraction 
Factor 
Initial Eigenvalues Rotation Sums of Squared 
Loadings 
 Total % of Variance Cumulative % Total 
1 3.294 54.897 54.897 2.689 
2 1.039 17.316 72.213 2.649 
 
Figure 4.4 Six items scree plot for Behavioral Intention 
However, when exploring the rotated structure of the two-factor solution five of 
the six items load highly (above |0.40|) onto both factors as shown in Table 4.9. The 
underlying TBP behavioral intention also does not have an underlying subscale and 
therefore BI was forced to one factor.  
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Table 4.9 Behavioral Intention Factor Loadings 
Item Factor Loadings 
 1 2 
B33 .442 -.924 
B34 .377 -.935 
B35 .532 -.554 
B36.1 .764 -.499 
B36.2 .797 -.558 
B36.3 .922 -.230 
 
Past Behavior  
 Lastly, a principal component analysis was conducted on the six items for past 
behavior. The KMO measured indicated an acceptable sampling for the analysis (KMO = 
0.587) and Bartlett’s Test of Sphericity x2 = 101.446, df = 15, p = 0.000. Similar to 
behavioral intention, initial analysis indicated items load onto two factors for past 
behavior as shown in Table 4.10 and by the scree plot in Figure 4.5. However, the TPB 
past behavior should demonstrate one factor in the model, but does ask about ever 
performing the behavior and performing in the past 30 days. The rotated factor structure 
in Table 4.11 shows items PB31.3 and PB32.3 asking about past behavior performing 
referral to treatment load onto the second factor. To align with the theoretical model, past 
behavior was forced into one factor, which explains 37.6% of the variance.  
Table 4.10 Total Variance Explained for Past Behavior: Factor Solution with 
PCA Extraction 
Factor 
Initial Eigenvalues Rotation Sums of Squared 
Loadings 
 Total % of Variance Cumulative % Total 
1 2.256 37.595 37.595 2.034 
2 1.146 19.098 56.693 1.609 
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Figure 4.5 Past Behavior Scree plot for six item 
 
Table 4.11 Past Behavior Factor Loadings 
Item Factor Loadings 
 1 2 
PB31.1 .754 .259 
PB31.2 .703 .322 
PB31.3 .242 .802 
PB32.1 .668 -.076 
PB32.2 .650 .259 
PB32.3 .211 .850 
 
Reliability 
Based on the factor analysis of the 48 items, eight factors were derived.  
Cronbach’s alpha tests were computed to determine if the factor subscales were reliable. 
Cronbach’s alpha tests supported findings from the factor analysis, and overall, data 
indicated strong internal subscale consistency except for past behavior. The subscale 
alpha scores were determined as follows: attitude behavioral belief (questions A13-16; α 
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= 0.816), attitude evaluation (A17-19; α = 0.885), subjective norms normative belief 
(S20, S24; α = 0.859), subjective norms motivation to comply (S21-23; α = 0.911), 
perceived behavioral control; control belief (P27; α = 0.853), perceived behavioral 
control perceived power (P26, P28-30; α = 0.762), behavioral intention (BI33-36; α = 
0.830), and past behavior (PB31-32; α = 0.661). Scores 0.80 and above indicated good 
internal consistency reliability, while scores 0.60 and above indicate adequate 
consistency. Overall, the data illustrated strong internal reliability on seven of the eight 
subscales.  
Correlation 
 Pearson correlations were computed on each of the TPB subscales that appeared 
through factor analysis. The correlation was used to examine the relationships between 
the subscales and can be found in Table 4.12. The first column shows the correlations of 
other variables with attitude behavioral belief (factor 1), the second column shows the 
correlation of other variables with attitude evaluation (factor 2), and so on. Overall, 
positive correlations were found between behavioral intention and the other TPB 
constructs. Six out of the seven variables in the TPB model to determine behavioral 
intention are significantly correlated to behavioral intention. Attitude behavioral belief 
(.693), subjective norms normative belief (.571), perceived behavioral control perceived 
power (.550), and past behavior (.649) all have a large relationship with behavioral 
intention based on Cohen’s guidelines outlined in the Methods section. Attitude 
evaluation (-.265) and perceived behavioral control control belief (-.238) have a medium 
relationship while subjective norms motivation to comply (.161) shows to have a weak 
relationship. 
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Table 4.12 Subscale Bivariate Correlation 
Factor 1 2 3 4 5 6 7 8 
Attitude 
Behavioral 
Belief 
1        
Attitude 
Responsibility 
-.274** 1       
Motivation to 
comply 
.094 .046 1      
Normative 
Beliefs 
.602** -.103 .259** 1     
Control Belief -.266** .454** .003 -.123 1    
Perceived 
Power 
.339** -.071 .019 .228* -.125 1   
Past Behavior .402** .032 .124 .396** -.036 .491** 1  
Intention .693** -.265** .161 .571** -.238* .550** .649** 1 
**Correlation is significant at the 0.01 level (2-tailed). 
 * Correlation is significant at the 0.05 level (2-tailed). 
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CHAPTER FIVE: DISCUSSION 
 The primary goal of this study was to adapt a TPB-based instrument to measure 
pharmacists’ perceptions toward using SBIRT and to test initial reliability and validity. 
These results offer a foundation for future research to build on the instrument and inform 
pharmacist readiness in prescription misuse early intervention strategies. This chapter 
summarizes the findings from the factor analysis of the 48-items for the TPB and 
implications for exploring an SBIRT pilot in an Idaho pharmacy setting. Limitations of 
this study as well as suggestions for future research are also addressed in this chapter.  
Defining and Refining Underlying Factor Structure  
 Factor analysis of the theory of planned behavior constructs in the instrument 
supported the eight-factor solution that was conceptually hypothesized. As mentioned in 
Chapter 3, items were retained if it loaded onto a factor with an absolute value of 0.40 or 
more and shared a conceptual meaning.  
Attitude 
In the Theory of Planned Behavior, the construct attitude is determined by two 
underlying themes: behavioral beliefs and evaluation. Behavioral belief captures if 
SBIRT performance is associated with certain attributes or outcomes while evaluation 
aims to capture values attached to the behavioral outcome (Glanz et al., 1996). Under 
attitude, six items loaded onto factor one above |0.40| and were developed to characterize 
behavioral beliefs. Three items loaded onto factor two above |0.80| but appeared to 
represent who is responsible to screen and intervene more so than the sub-construct 
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evaluation, which was the original intended latent construct for those items. Factor one 
items included A13 that captured beliefs if prescription opioid misuse was a problem in 
their community, A14.1-14.3 that captured if using SBIRT behaviors “…would be useful 
to use in cases of prescription opioid misuse,” and A15-16 that captured if pharmacists 
considered SBI a professional duty. These items capture if pharmacists consider opioid 
misuse a problem in their community, if they consider screening and intervening a 
professional duty, and if they believe it would be useful to use SBIRT in instances where 
misuse is suspected. Combined, these items appear to measure more than just behavioral 
beliefs and could measure a more general attitude towards SBIRT and if misuse is a 
problem in their community.  
Three items under attitude loaded onto a second factor well over the established 
benchmark of |0.40|. The evaluation subtheme in attitude was intended to be measured by 
instrument items A15-19 to capture if values of professional duty and responsibility 
would motivate pharmacists to use SBIRT. However, after analysis, it appears items 
A17-19 appear to capture pharmacists’ perception towards who is more responsible in 
early intervention strategies, which is not a TPB construct in attitude. Therefore, with the 
items A15-16 loading onto factor one, and the content in items A17-19, the subscales 
were labeled “attitude” and “responsibility” rather than “behavioral belief” and 
“evaluation” as outlined in the model.  
Subjective Norms 
The TPB notes that normative beliefs and motivation to comply make up the 
construct subjective norms. Normative beliefs capture perceptions towards whether each 
referent approves or disapproves of the behaviors while motivation to comply captures 
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the motivation to do what each referent thinks (Glanz et al., 1996). In subjective norms, 
nine items loaded onto factor one above |0.70| and appeared to represent motivation to 
comply while six items loaded onto factor two above |0.60| for normative belief. Without 
being forced into two factors, analysis revealed ambiguous factor loadings for subjective 
norms with 5-6 interpretable factors. This could mean that pharmacists consider the 
approval of their supervisor, other pharmacists, and friends/family differently and are 
motivated to comply with what each referent thinks differently. For example, factor one 
clustered together for normative beliefs for supervisors and other pharmacists, which 
aligns well with the TPB. However, factor two hangs together for motivation to comply 
with other pharmacists, while factor three hangs together for motivation to comply with 
supervisors. This could mean that pharmacists are motivated differently by their 
supervisors compared to other pharmacists. Additionally, factor four captures motivation 
to comply with friends and family and factor five captures normative beliefs for friends 
and family.  
To represent the theory, subjective norms were forced to two factors and 
explained 57.2% of the variance in the overall construct. When forced to two factors, 
motivation to comply with each of the three referents clustered onto factor one as 
originally intended to follow the theory. Items that capture normative beliefs for other 
pharmacists and supervisors again clustered onto the same factor as predicted in the TPB 
model. However, item S25.1-25.3 that captures whether respondents believe friends and 
family think they should use SBIRT revealed to hang on both factors. It is common for 
items to cross-load onto factors, but the three items loaded onto motivation to comply and 
normative beliefs at nearly the same level. This variance from the TPB is potentially due 
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to poor measurement, or that pharmacists answered the items in a similar way between 
normative beliefs and motivation to comply with friends or family. It could also mean 
that, to pharmacists, it does not matter what friends and family approve or disapprove of 
in the workplace. Items S25.1-25.3 were eliminated from the instrument because of 
ambiguous factor loadings. The themes that emerged in subjective norms were labeled 
“motivation to comply” and “subjective norms” because they reflected the underlying 
subconstructs in the TPB model.  
Research also indicates that, regarding subjective norms, pharmacists’ normative 
behavior may also be shaped by insurance companies and the provider-pharmacist 
relationships, potentially more so than friends or family (Fleming et al., 2019; Hagemeier 
et al., 2014). Pharmacists may also be influenced by regulatory entities such as the Board 
of Pharmacy or the Drug Enforcement Administration. These referents were not included 
in the instrument items in this study.  
Perceived Behavioral Control 
Perceived behavioral control (PCB) is also made up of two underlying constructs: 
perceived power and control belief. According to the TPB, perceived power aims to 
capture the perceived effect of a condition that makes performing the behavior easy or 
difficult, and control aims to capture the likelihood of the occurrence of each facilitating 
or constraining condition (Glanz et al., 1996). Initial analysis of PBC revealed three 
interpretable factor structures that appeared to measure ease of performing the behavior, 
confidence, and control. Since the construct of perceived behavioral control should 
measure (1) the ease of performing the behavior and (2) whether or not it is within the 
respondent’s control, the third interpretable factor could capture self-efficacy (confidence 
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to carry out behavior). Yet, when forced to two factors the two PBC subthemes emerged. 
The PBC construct was left at two factors because items P28 that emerged as the third 
interpretable factor for self-efficacy could also be considered a condition that makes 
behavioral performance difficult or easy. An example of this would be low confidence in 
referring a patient to treatment that would make performing the behavior more difficult. 
Additionally, P29 asks pharmacists whether having a relationship with the patient would 
make engaging patients in a discussion about prescription opioid misuse easy. The item 
asks if a relationship with the patient makes engaging the patient easier or more difficult, 
which aligns with the perceived power subtheme that captures the perceived effect of 
conditions that make behavioral perform easy or difficult. The two subscales in PBC 
were then labeled “perceived power” and “control belief” from the TPB conceptual 
model.  
Behavioral Intention and Past Behavior 
The analysis of behavioral intention, which captures the perceived likelihood of 
performing the behavior, and past behavior showed four interpretable factors based on 
the eigenvalues and scree plots. The two themes in behavioral intention appeared to 
delineate wanting to perform the behavior and intending to perform the behavior. This 
finding may reflect discrepancies in wanting to intervene in prescription misuse but 
pharmacists may not have the perceived behavioral control to do so. However, five of the 
six items in behavioral intention cross-loaded onto the two factors above |0.4|. In the TPB 
model, behavioral intention is a single outcome that is influenced by attitude, subjective 
norms, and perceived behavioral control. Due to the items cross-loading and following 
the theoretical model, behavioral intention was left at one factor.  
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Similarly, the six items in past behavior revealed two factors. Factor one appeared 
to delineate past the 30 days and ever performing SBI while factor two captured the past 
30 days and ever performing referral to treatment. The emergence of two factors is not 
surprising considering SBIRT is not currently used in a pharmacy setting and therefore 
past behavior will not be consistent across respondents. Previous studies also revealed 
that, although SBIRT is not systemically implemented in pharmacies, some pharmacists 
still appear to occasionally screen, briefly intervene, and/or refer a patient to treatment 
(Cochran et al., 2014; Hagemeier et al., 2014). Past behavior alpha scores were also 
lower than the other constructs due to variation in past experiences across the three 
behaviors. Similar to behavioral intention, past behavior was forced and left at one factor 
to follow the TPB model and because this factor measures past performances of the 
behavior and not a belief or attitude towards performing it.  
Across all behaviors, the reliability was supported by the internal consistency 
values for each construct that is reflected in high Cronbach’s coefficient alphas.  
One interesting finding of this study is that referral to treatment questions emerged 
differently in analysis than screening and brief intervention, particularly in behavioral 
intention and past behavior. This may suggest that pharmacists’ willingness to actively 
engage in SUD intervention is different than more passive behaviors like SBI. This 
concept has also been suggested by previous research that indicated pharmacists’ self-
efficacy in discussing treatment facility information with patients is low (Hagemeier et 
al., 2014). Furthermore, pharmacists appear more cautious making the leap from just 
screening and engaging in a discussion to all three SBIRT behaviors (Riley & Alemagno, 
2019).  
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Lastly, practice setting is supported in the research in potentially influencing 
perceptions, behavioral performance, and barriers to providing SBIRT in a pharmacy 
setting (Cochran et al., 2015). Therefore, the demographics questions capturing education 
level, age, gender, practice setting, and amount of education about this topic remained in 
the tool. Furthermore, when administering a TPB-based questionnaire, items from each 
construct should be presented in a non-systemic order rather than by construct like what 
was done in the pilot instrument.   
Correlation 
The Theory of Planned Behavior posits that the more favorable attitude and 
subjective norms and the higher perceived behavioral control are the stronger a person 
intends to perform the behavior. The Pearson correlation was used to test initial 
relationships between TPB constructs measured in the instrument and behavioral 
intention to determine if the items align with the model. The correlation showed 
significant relationships at 0.01 between behavioral intention and attitude, attitude 
responsibility, subjective norms normative beliefs, perceived behavioral control 
perceived power, and past behavior. There was also a significant relationship at the 0.05 
level between behavioral intention and perceived behavioral control control belief, but 
there was no significant relationship between motivations to comply and intention. The 
motivation to comply subconstruct hangs together well in factor analysis and shows high 
internal consistency, however it does not have a large influence on behavioral intention or 
even past behavior. Motivation to comply also does affect any of the constructs (except 
normative beliefs) or outcomes, which may indicate that it does not have an effect on 
pharmacists using SBIRT. This could also be due to how the questions were written or, as 
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mentioned above, was looking at the wrong referents. The previous study used to adapt 
items asked about “most people who are important to me” and “other pharmacists” for 
motivation to comply. These items were split between referents believed to influence 
participants: friends/family, other pharmacists, and supervisors.  
Limitations 
Limitations of this study include sampling issues. To begin, the distribution list of 
pharmacists still captured participants working in a hospital. If participants were currently 
practicing, their responses were left in psychometric testing to maintain an adequate 
number of responses needed for tests because of the small sample size. Secondly, there 
was a low response rate. The low response rate could be due to several reasons including 
fatigue in discussing prescription opioid misuse or responding to opioid-related surveys. 
There is also a possibility that pharmacists are tired of responding to surveys because of 
numerous email invitations received to participate in studies. Additionally, the email 
distribution was sent from a Boise State University address and participants may be more 
likely to respond had it come from a pharmacy association, the Board of Pharmacy, or the 
College of Pharmacy at Idaho State University.  
Another limitation of this study is adapting the survey items from a previous tool 
rather than eliciting salient beliefs about the combined SBIRT behaviors before survey 
development. Although the questions were derived from the TPB tool on utilizing the 
prescription monitoring program, which could be considered the first step in screening 
for misuse, the perceptions toward brief intervention and referral to treatment could be 
much different. The nature of the self-report survey instrument is another limitation in 
this study. Some caution should be given when using self-report measures when testing 
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reliability and validity. Using multiple methods such as interviews or focus groups in 
addition to self-report would provide more measures to ensure validity and reliability. 
Finally, another limitation in this study could be practicing pharmacists’ general 
understanding of what SBIRT is since they are not typically trained in SBIRT or use it in 
daily practice. The SAMHSA SBIRT definitions were provided in the survey, however, 
the interpretation of a universal screening or brief intervention could vary in participants.  
Suggestions for Future Research 
Future research could take numerous directions following this study. This study 
developed one of the first TPB-based instruments that look at pharmacists’ perceptions 
toward all three SBIRT behaviors for prescription misuse. The results from this study 
suggest future research is needed to continue testing the validity and reliability of the 
tool, such as conducting test-retest reliability or conducting a Confirmatory Factor 
Analysis to test the TPB. There is also a need to take an in-depth look into the subscales 
that varied from the TPB model, such as subjective norms and attitude. For example, a 
deeper dive into motivation to comply and normative beliefs is needed to determine if the 
referents chosen have the most impactful influence on pharmacists’ workplace decisions. 
A previous study by Fleming et al. (2019) gathered pharmacists’ salient normative beliefs 
towards their willingness to engage patients in a discussion and then refer indicated 
prescribing physicians as an influential referent in their decision. Other referents that 
appeared were regulatory agencies like the DEA or pharmacy boards, employers in 
addition to direct supervisors, and possibly patients. In previous research, pharmacists 
who felt they had a right to ask about misuse were twice as likely to engage patients in a 
discussion about it (Cochran et al., 2015). Pharmacists who felt their patients believed the 
51 
 
pharmacists had a right to ask were 88% more likely to discuss misuse. Considering the 
limitations in the self-report measures, future studies may also consider using other 
measures to investigate perceptions toward implementing SBIRT. Examples could 
include qualitative measures such as focus groups or interviews, or piloting the model to 
gain a more comprehensive understanding.  
Future research should also consider the difference in perceptions for 
implementing SBI and referral to treatment. Initial analysis showed that attitude, 
subjective norms, and perceived behavioral control toward referral to treatment may be 
different from screening and brief intervention. This is supported in the research that 
patients and pharmacists alike are more apprehensive toward referral to treatment for 
substance use than the other behaviors (Riley & Alemango, 2018). Some research 
indicates this could be mitigated by more dissemination of prescription opioid-specific 
continuing education, improving self-efficacy beliefs, and dissemination of addiction 
treatment information (Hagemeier et al., 2014). Finally, this instrument only focused on 
early intervention for prescription opioid misuse. However, future studies may want to 
consider examining other commonly misused controlled substances such as 
benzodiazepines or sedatives.  
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Pharmacists’ Perceptions Toward Prescription Opioid Misuse: Development of a 
valid and reliable survey questionnaire 
 
From: Boise State University, College of Health Sciences 
Subject line: Invitation: Participate in Idaho Pharmacy Survey 
Feedback Requested: Idaho Pharmacy Survey 
 
Good morning, 
 
A graduate student at Boise State University is conducting a pilot research study designed 
to develop a valid and reliable survey questionnaire. The purpose of this pilot study is to 
explore Idaho pharmacists’ perceptions toward screening patients for prescription opioid 
misuse, briefly intervening with feedback and advice, and referring patients to treatment 
if needed.  
 
Your responses are voluntary and will be kept confidential. This survey should take 
approximately 15-20 minutes to complete. You must be a pharmacist who is currently 
practicing in the state of Idaho. We appreciate your response by April 18, 2019.  
 
If you consent to participate, please complete the following survey. 
 
If you have any questions regarding the survey or its purpose, please send inquiries to:  
Tara Fouts Dr. Sarah Toevs 
Community & Environmental Health Community & Environmental Health  
tarafouts@u.boisestate.edu stoevs@boisestate.edu  
 
If you have questions about your rights as a research participant, you may contact the 
Boise State University Institutional Review Board (IRB), which is concerned with the 
protection of volunteers in research projects.  You may reach the board office between 
8:00 AM and 5:00 PM, Monday through Friday, by calling (208) 426-5401 or by writing: 
Institutional Review Board, Office of Research Compliance, Boise State University, 1910 
University Dr., Boise, ID 83725-1138. 
We appreciate your participation in this survey. 
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Theory of Planned Behavior Construct Matrix and Key 
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Construct 
Behavior 1 
Screen patients for 
risky substance use 
behaviors 
Behavior 2 
Engage patients in a 
short discussion 
about substance 
misuse and opioid 
use disorder (OUD) 
Behavior 3 
Referral to 
Treatment 
Attitude 
 Q13 Prescription 
opioid misuse is a 
problem in my 
community. 
  
Behavioral 
Belief:  
Belief that 
behavioral 
performance is 
associated with 
certain attributes 
or outcomes 
Q14.1 When the 
validity of an opioid 
prescription is in 
question, I believe it 
would be useful for 
a pharmacist to: 
screen patients for 
prescription opioid 
misuse.  
Q14.2 When the 
validity of an opioid 
prescription is in 
question, I believe it 
would be useful for a 
pharmacist to: 
briefly intervene by 
providing feedback 
and advice.  
Q14.3 When the 
validity of an opioid 
prescription is in 
question, I believe it 
would be useful for 
a pharmacist to: 
advise patients to 
consult their 
prescriber 
Evaluation: 
Value attached 
to a behavioral 
outcome or 
attribute 
Q15 I believe it is a 
pharmacist’s 
professional duty to 
screen patients for 
prescription opioid 
misuse.  
Q16 I believe it is a 
pharmacist’s 
professional duty to 
briefly intervene 
with feedback and 
advice when patients 
show risky 
prescription opioid 
use.  
 
 Q17 Overall, 
prescribers are more 
responsible than 
pharmacists are to 
engage patients in a 
short discussion 
about prescription 
opioid abuse and 
misuse.  
Q18 Overall, 
prescribers are more 
responsible than 
pharmacists are to 
screen for 
prescription opioid 
abuse and misuse. 
Q19 Overall, 
prescribers are more 
responsible than 
pharmacists are to 
refer to treatment for 
prescription opioid 
misuse and abuse.  
Subjective Norms 
Normative 
Belief: Belief 
about whether 
each referent 
approves or 
disapproves of 
the behavior 
Q20.1 Considering 
pharmacists whose 
opinions you value, 
to what extent do 
you agree they 
would: screen 
patients for 
Q20.2 Considering 
pharmacists whose 
opinions you values, 
to what extent do 
you agree they 
would: briefly 
intervene with 
Q20.3 Considering 
pharmacists whose 
opinions you values, 
to what extent do 
you agree they 
would: refer patients 
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prescription opioid 
misuse?  
feedback and advice 
about opioid misuse? 
to treatment 
resources if needed? 
 Q24.1 How much 
do you agree that 
your supervisor 
thinks you should 
screen patients for 
prescription opioid 
misuse?  
Q24.2 How much do 
you agree that your 
supervisor thinks 
you should briefly 
intervene with 
feedback and advice 
about prescription 
opioid misuse? 
Q24.3 How much do 
you agree that your 
supervisor thinks 
you should refer a 
patient to treatment 
if needed.  
Motivation to 
comply: 
Motivation to do 
what each 
referent thinks 
Q21.1 When it 
comes to screening 
patients for 
prescription opioid 
misuse, I want to do 
what my supervisor 
thinks I should do.   
Q22.1 When it 
comes to providing 
patients feedback 
and advice about 
prescription opioid 
misuse, I want to do 
what my supervisor 
thinks I should do 
Q23.1 When it 
comes to referring 
patients to additional 
treatment resources, 
I want to do what 
my supervisor thinks 
I should do.  
 Q21.2 I want to do 
what other 
pharmacists who 
opinions I value 
think I should do 
Q22.2 I want to do 
what my 
friends/family think 
I should do 
Q23.2 I want to do 
what my 
friends/family think 
I should do.  
 Q21.3 I want to do 
what my 
friends/family think 
I should do 
Q22.3 I want to do 
what other 
pharmacists whose 
opinions I value 
think I should do 
Q23.3 I want to do 
what other 
pharmacists whose 
opinions I value 
think I should do 
Perceived Behavioral Control 
Control belief: 
Perceived 
likelihood of 
occurrence of 
each facilitating 
or constraining 
condition 
Q27.1 The decision 
to screen patients for 
prescription opioid 
misuse is beyond 
my control.  
Q27.2 The decision 
to briefly intervene 
with feedback and 
advice is beyond my 
control.  
Q27.3 The decision 
to refer patients to 
treatment is beyond 
my control.  
Perceived 
power: 
Perceived effect 
of each condition 
in making 
behavioral 
performance 
difficult or easy 
 Q26 How much do 
you agree with this 
statement: Engaging 
patients in a 
discussion relating to 
prescription opioid 
misuse would be 
easy for me.  
 
 Q28.1 I am 
confident in my 
Q28.2 I am 
confident in my 
Q28.3 I am 
confident in my 
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ability to screen 
patients for 
prescription opioid 
misuse 
ability to briefly 
intervene with 
feedback and advice 
ability to refer a 
patient to treatment 
if needed.  
  Q29 For me, 
questioning a patient 
with whom I have a 
relationship with 
about the legitimacy 
of a PO would be 
easy/difficult 
 
  Q30 For me, 
questioning a patient 
with whom I have 
no strong 
relationship with 
about the legitimacy 
of a PO would be 
easy/difficult 
 
Past Behavior 
 Q31.1 In the past 30 
days, have you 
screened a patient 
for prescription 
opioid misuse?  
Q31.2 In the past 30 
days, have you 
Briefly intervened 
with feedback and 
advice?  
Q31.3 In the past 30 
days, have you 
Referred a patient to 
additional treatment 
resources?  
 Q32.1 In your 
pharmacy practice, 
have you ever 
screened a patient 
for prescription 
opioid misuse? 
Q32.2 In your 
pharmacy practice, 
have you ever 
briefly intervened 
with feedback and 
advice? 
Q32.3 In your 
pharmacy practice, 
have you ever 
referred a patient to 
additional treatment 
resources? 
Behavioral Intention 
Perceived 
likelihood of 
performing the 
behavior 
Q33 How much, if 
any, do you intend 
to screen patients for 
prescription opioid 
misuse? 
Q34 How much, if 
any, do you intend to 
briefly intervene 
with feedback and 
advice for 
prescription opioid 
misuse?  
Q35 How much, if 
any, do you intend to 
refer patients to 
additional treatment 
resources if needed?  
 Q36.1 I want to 
screen patients for 
prescription opioid 
misuse 
Q36.2 I want to 
briefly intervene 
with feedback and 
advice for 
prescription opioid 
misuse 
Q36.3 I want to refer 
patients to additional 
resources if they 
need it.  
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APPENDIX D 
Piloted Instrument 
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Q1 Do you currently provide patient care in a community pharmacy setting? 
___Yes 
___No 
Q2 On average, how many hours per week do you work in a community pharmacy? 
 
Q3 Approximately how many years have you been practicing pharmacy? 
 
Q4 What best describes your primary practice site? 
___Grocery or drug store chain (i.e. Sav-on, Rite-Aid) 
___Independent pharmacy 
___Mass merchandiser (i.e. Walmart) 
___Outpatient/clinic pharmacy 
___Health system pharmacy 
___Other (please specify)  
 
Q5 Please select the Idaho county in which you primarily practice. 
▼ Ada ... Washington 
 
Q6 Please indicate your highest level of education completed.  
___Bachelor 
___Master 
___PharmD 
___Other (please specify) 
 
Q7 What year did you graduate with your highest pharmacy degree? 
 
Q8 Since graduation, approximately how many Continuing Education training hours have 
you completed for opioid use disorder? 
 
Q9 On average, how many opioid prescriptions do you fill in a week? 
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Q10 Please indicate your sex. 
___Male 
___Female 
___Other (please specify)  
 
Q11 What year were you born? 
 
Q12 Please consider your community pharmacy practice and the definitions below when 
answering the following questions. 
 
Prescription opioid misuse: using a prescription in a manner other than directed by a 
doctor including using in greater amounts than prescribed, more often, or for longer 
periods than instructed.  
Screening: a healthcare professional assessing a patient for risky substance use behavior 
using a standardized screening tool. 
 
Brief intervention: engaging a patient showing risky substance use behaviors in a short 
conversation providing feedback and advice. Depending on the severity or risk for 
adverse consequences, a 5-10 minute discussion or longer 20-30 minute discussion 
provides the patient with personalized feedback showing concern over prescription use. 
 
Referral to treatment: providing a referral to brief therapy or additional treatment to 
those who screen in need of additional services. 
 
Q13. How much do you agree with this statement: Prescription opioid misuse is a 
problem in my community. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q14. When the validity of an opioid prescription is in question, I believe it would be 
useful for a pharmacist to: 
 
 Strongly agree Agree 
Somewhat 
agree 
Neither 
agree 
nor 
disagree 
Somewhat 
disagree Disagree 
Strongly 
disagree 
Screen 
patients for 
prescription 
opioid 
misuse 
O O O O O O O 
Briefly 
intervene by 
providing 
feedback 
and advice 
O O O O O O O 
Advise 
patients to 
consult their 
prescriber 
O O O O O O O 
 
Q15 I believe it is a pharmacist's professional duty to screen patients for prescription 
opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q16 I believe it is a pharmacist's professional duty to briefly intervene with feedback and 
advice when patients show risky prescription opioid use. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q17 Overall, prescribers are more responsible than pharmacists are for screening patients 
for prescription opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q18 Overall, prescribers are more responsible than pharmacists are for briefly 
intervening with feedback and advice on prescription opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q19 Overall, prescribers are more responsible than pharmacists are for referring people 
to treatment for prescription opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q20 Considering pharmacists whose opinions you value, to what extent do you agree 
they would: 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
Screen patients 
for prescription 
opioid misuse? 
O O O O O O O 
Briefly intervene 
with feedback 
and advice? 
O O O O O O O 
Refer patients to 
treatment 
resources if 
necessary? 
O O O O O O O 
 
Q21  When it comes to screening patients for prescription opioid misuse, 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
I want to do 
what my 
supervisor 
thinks I should 
do 
O O O O O O O 
I want to do 
what other 
pharmacists 
whose opinions I 
value think I 
should do 
O O O O O O O 
I want to do 
what my 
friends/family 
think I should do 
O O O O O O O 
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Q22 When it comes to providing patients feedback and advice about prescription opioid 
misuse, 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
I want to do 
what my 
supervisor 
thinks I should 
do 
O O O O O O O 
I want to do 
what my 
friends/family 
think I should do 
O O O O O O O 
I want to do 
what other 
pharmacists 
whose opinions I 
value think I 
should do 
O O O O O O O 
 
Q23 When it comes to referring patients to additional treatment resources, 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
I want to do 
what my 
supervisor 
thinks I should 
do 
O O O O O O O 
I want to do 
what my 
friends/family 
think I should do 
O O O O O O O 
I want to do 
what other 
pharmacists 
whose opinions I 
value think I 
should do 
O O O O O O O 
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Q24 How much do you agree that your supervisor thinks you should: 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
Screen patients 
for prescription 
opioid misuse 
O O O O O O O 
Briefly 
intervene with 
feedback and 
advice about 
opioid misuse 
O O O O O O O 
Refer a patient 
to treatment if 
needed 
O O O O O O O 
 
Q25 How much do you agree that your friends/family think you should: 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
Screen patients 
for prescription 
opioid misuse 
O O O O O O O 
Briefly intervene 
with feedback 
and advice about 
opioid misuse 
O O O O O O O 
Refer a patient 
to treatment if 
needed 
O O O O O O O 
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Q26 How much do you agree with this statement: Engaging patients in a discussion 
relating to prescription opioid misuse would be easy for me. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q27 How much do you agree with each statement? 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
The decision to 
screen patients 
for prescription 
opioid misuse is 
beyond my 
control 
O O O O O O O 
The decision to 
briefly intervene 
with feedback 
and advice is 
beyond my 
control 
O O O O O O O 
The decision to 
refer patients to 
treatment is 
beyond my 
control 
O O O O O O O 
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Q28 I am confident in my ability to do the following: 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
Screen patients 
for prescription 
opioid misuse 
O O O O O O O 
Briefly intervene 
with feedback 
and advice about 
opioid misuse 
O O O O O O O 
Refer a patient 
to treatment if 
needed 
O O O O O O O 
 
Q29 Questioning a patient with whom I have a relationship about the legitimacy of an 
opioid prescription would be easy for me. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q30 Questioning a patient with whom I have no strong relationship about the 
legitimacy of an opioid prescription would be easy. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q31 In the past 30 days, have you: 
 Yes No 
Screened a patient for 
prescription opioid misuse? O O 
Briefly intervened with 
feedback and advice? O O 
Referred a patient to 
additional treatment 
resources? 
O O 
 
Q32 In your pharmacy practice, have you ever: 
 Yes No 
Screened a patient for 
prescription opioid misuse? O O 
Briefly intervened with 
feedback and advice? O O 
Referred a patient to 
additional treatment 
resources? 
O O 
 
Q33 How much, if any, do you intend to screen patients for prescription opioid misuse? 
         
Extremely 
likely 
O O O O O O O Extremely 
unlikely 
 
Q34 How much, if any, do you intend to briefly intervene with feedback and advice for 
prescription opioid misuse? 
         
Extremely 
likely 
O O O O O O O Extremely 
unlikely 
 
Q35 How much, if any, do you intend to refer patients to additional treatment resources 
when needed? 
         
Extremely 
likely 
O O O O O O O Extremely 
unlikely 
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Q36 Please indicate how much you agree with each statement. 
 Strongly agree . . 
Neither 
agree 
nor 
disagree 
. . Strongly disagree 
I want to briefly 
intervene with 
feedback and 
advice for 
prescription 
opioid misuse 
O O O O O O O 
I want to screen 
patients for 
prescription 
opioid misuse 
O O O O O O O 
I want to refer 
patients to 
additional 
resources if they 
need it 
O O O O O O O 
 
Q37 What, if anything, prevents you from screening for opioid misuse, briefly 
intervening, referring to treatment? (Please select up to three) 
___Lack of time with other job-related duties 
___Lack of privacy to discuss with patients 
___Lack of reimbursement/compensation 
___Repercussions from employer 
___Language barrier with patients 
___Workflow does not allow 
___Lack of knowledge about opioid misuse 
___Lack of knowledge about available treatment resources 
___Fear of prescribers' response 
___Fear of personal harm from the patient 
___Limited information about patient's medical history 
___Fear of legal liability or litigation 
___Fear of losing rapport with patients 
___Fear of accidentally stigmatizing patients as addicts 
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___Not enough rapport with patient 
___Too little or no training 
___Patients unwilling to talk/listen 
___Do not know how to initiate conversation 
___Other (please specify) 
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Q13. How much do you agree with this statement: Prescription opioid misuse is a 
problem in my community? 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Please indicate how much you agree or disagree with each s 
 
Q14. When the validity of an opioid prescription is in question, I believe it would be 
useful for a pharmacist to: 
 Strongly agree Agree 
Somewhat 
agree 
Neither 
agree 
nor 
disagree 
Somewhat 
disagree Disagree 
Strongly 
disagree 
Screen 
patients for 
prescription 
opioid 
misuse 
O O O O O O O 
Briefly 
intervene 
by 
providing 
feedback 
and advice 
O O O O O O O 
Advise 
patients to 
consult 
their 
prescriber 
O O O O O O O 
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Q15 I believe it is a pharmacist's professional duty to screen patients for prescription 
opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q16 I believe it is a pharmacist's professional duty to briefly intervene with feedback and 
advice when patients show risky prescription opioid use. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q17 Overall, prescribers are more responsible than pharmacists are for screening patients 
for prescription opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q18 Overall, prescribers are more responsible than pharmacists are for briefly 
intervening with feedback and advice on prescription opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q19 Overall, prescribers are more responsible than pharmacists are for referring people 
to treatment for prescription opioid misuse. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q20 Considering pharmacists whose opinions you value, to what extent do you agree 
they would: 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
Screen patients 
for prescription 
opioid misuse? 
O O O O O O O 
Briefly intervene 
with feedback 
and advice? 
O O O O O O O 
Refer patients to 
treatment 
resources if 
necessary? 
O O O O O O O 
 
Q21  When it comes to screening patients for prescription opioid misuse, 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
I want to do 
what my 
supervisor 
thinks I should 
do 
O O O O O O O 
I want to do 
what other 
pharmacists 
whose opinions I 
value think I 
should do 
O O O O O O O 
I want to do 
what my 
friends/family 
think I should do 
O O O O O O O 
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Q22 When it comes to providing patients feedback and advice about prescription opioid 
misuse, 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
I want to do 
what my 
supervisor 
thinks I should 
do 
O O O O O O O 
I want to do 
what my 
friends/family 
think I should do 
O O O O O O O 
I want to do 
what other 
pharmacists 
whose opinions I 
value think I 
should do 
O O O O O O O 
 
Q23 When it comes to referring patients to additional treatment resources, 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
I want to do 
what my 
supervisor 
thinks I should 
do 
O O O O O O O 
I want to do 
what my 
friends/family 
think I should do 
O O O O O O O 
I want to do 
what other 
pharmacists 
whose opinions I 
value think I 
should do 
O O O O O O O 
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Q24 How much do you agree that your supervisor thinks you should: 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
Screen patients 
for prescription 
opioid misuse 
O O O O O O O 
Briefly 
intervene with 
feedback and 
advice about 
opioid misuse 
O O O O O O O 
Refer a patient 
to treatment if 
needed 
O O O O O O O 
 
Q25 How much do you agree with this statement: Engaging patients in a discussion 
relating to prescription opioid misuse would be easy for me. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
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Q26 How much do you agree with each statement? 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
The decision to 
screen patients 
for prescription 
opioid misuse is 
beyond my 
control 
O O O O O O O 
The decision to 
briefly intervene 
with feedback 
and advice is 
beyond my 
control 
O O O O O O O 
The decision to 
refer patients to 
treatment is 
beyond my 
control 
O O O O O O O 
 
Q27 I am confident in my ability to do the following: 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
Screen patients 
for prescription 
opioid misuse 
O O O O O O O 
Briefly intervene 
with feedback 
and advice about 
opioid misuse 
O O O O O O O 
Refer a patient 
to treatment if 
needed 
O O O O O O O 
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Q28 Questioning a patient with whom I have a relationship about the legitimacy of an 
opioid prescription would be easy for me. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q29 Questioning a patient with whom I have no strong relationship about the 
legitimacy of an opioid prescription would be easy. 
___Strongly agree 
___Agree 
___Somewhat agree 
___Neither agree nor disagree 
___Somewhat disagree 
___Disagree 
___Strongly disagree 
 
Q30 In the past 30 days, have you: 
 Yes No 
Screened a patient for 
prescription opioid misuse? O O 
Briefly intervened with 
feedback and advice? O O 
Referred a patient to 
additional treatment 
resources? 
O O 
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Q31 In your pharmacy practice, have you ever: 
 Yes No 
Screened a patient for 
prescription opioid misuse? O O 
Briefly intervened with 
feedback and advice? O O 
Referred a patient to 
additional treatment 
resources? 
O O 
 
Q32 How much, if any, do you intend to screen patients for prescription opioid misuse? 
         
Extremely 
likely 
O O O O O O O Extremely 
unlikely 
 
Q33 How much, if any, do you intend to briefly intervene with feedback and advice for 
prescription opioid misuse? 
         
Extremely 
likely 
O O O O O O O Extremely 
unlikely 
 
Q34 How much, if any, do you intend to refer patients to additional treatment resources 
when needed? 
         
Extremely 
likely 
O O O O O O O Extremely 
unlikely 
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Q35 Please indicate how much you agree with each statement. 
 Strongly agree . . 
Neither 
agree nor 
disagree 
. . Strongly disagree 
I want to briefly 
intervene with 
feedback and 
advice for 
prescription 
opioid misuse 
O O O O O O O 
I want to screen 
patients for 
prescription 
opioid misuse 
O O O O O O O 
I want to refer 
patients to 
additional 
resources if they 
need it 
O O O O O O O 
 
